These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacologic Agents for the Treatment of Vasodilatory Shock. Knotzer H; Poidinger B; Kleinsasser A Curr Pharm Des; 2019; 25(19):2133-2139. PubMed ID: 31272348 [TBL] [Abstract][Full Text] [Related]
3. Vasopressor therapy in critically ill patients with shock. Russell JA Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370 [TBL] [Abstract][Full Text] [Related]
4. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock. Albertson TE; Chenoweth JA; Lewis JC; Pugashetti JV; Sandrock CE; Morrissey BM Expert Rev Clin Pharmacol; 2022 Aug; 15(8):959-976. PubMed ID: 35920615 [TBL] [Abstract][Full Text] [Related]
5. [Arginine vasopressin in vasodilatory shock: a new therapy approach?]. Dünser M; Wenzel V; Mayr AJ; Hasibeder WR Anaesthesist; 2002 Aug; 51(8):650-9; discussion 659-60. PubMed ID: 12391525 [TBL] [Abstract][Full Text] [Related]
7. Concomitant vasopressin and hydrocortisone therapy on short-term hemodynamic effects and vasopressor requirements in refractory septic shock. Buckley MS; MacLaren R J Crit Care; 2017 Dec; 42():6-11. PubMed ID: 28647651 [TBL] [Abstract][Full Text] [Related]
8. Vasopressor Therapy in the Intensive Care Unit. Russell JA; Gordon AC; Williams MD; Boyd JH; Walley KR; Kissoon N Semin Respir Crit Care Med; 2021 Feb; 42(1):59-77. PubMed ID: 32820475 [TBL] [Abstract][Full Text] [Related]
9. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies. Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515 [TBL] [Abstract][Full Text] [Related]
10. The role of vasopressin in the treatment of vasodilation in shock states. Rozenfeld V; Cheng JW Ann Pharmacother; 2000 Feb; 34(2):250-4. PubMed ID: 10676834 [TBL] [Abstract][Full Text] [Related]
11. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin. Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use. Wieruszewski PM; Wittwer ED; Kashani KB; Brown DR; Butler SO; Clark AM; Cooper CJ; Davison DL; Gajic O; Gunnerson KJ; Tendler R; Mara KC; Barreto EF Chest; 2021 Feb; 159(2):596-605. PubMed ID: 32882250 [TBL] [Abstract][Full Text] [Related]
13. Vasoplegic syndrome after cardiovascular surgery: A review of pathophysiology and outcome-oriented therapeutic management. Datt V; Wadhhwa R; Sharma V; Virmani S; Minhas HS; Malik S J Card Surg; 2021 Oct; 36(10):3749-3760. PubMed ID: 34251716 [TBL] [Abstract][Full Text] [Related]
15. Management of vasodilatory shock: defining the role of arginine vasopressin. Dunser MW; Wenzel V; Mayr AJ; Hasibeder WR Drugs; 2003; 63(3):237-56. PubMed ID: 12534330 [TBL] [Abstract][Full Text] [Related]
16. Advances in Vasodilatory Shock: A Concise Review. Lahiry S; Thakur S; Chakraborty DS Indian J Crit Care Med; 2019 Oct; 23(10):475-480. PubMed ID: 31749557 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in perioperative anesthetic management update on the role of vasopressin and its effects on outcomes. Udeh CI; Diaz-Gómez JL; Anthony D; Satyapriya A; Perez-Protto S; Hata JS Curr Pharm Des; 2012; 18(38):6308-13. PubMed ID: 22762470 [TBL] [Abstract][Full Text] [Related]